| 2044 | Humans |
| 1534 | Female |
| 1362 | Male |
| 1205 | Adult |
| 722 | Adolescent |
| 681 | Middle Aged |
| 646 | Young Adult |
| 613 | HIV Infections (epidemiology) |
| 607 | Socioeconomic Factors |
| 573 | HIV Infections (drug therapy) |
| 497 | HIV Infections (prevention & control) |
| 431 | South Africa |
| 383 | South Africa (epidemiology) |
| 350 | HIV Infections (psychology) |
| 322 | Risk Factors |
| 304 | Prevalence |
| 297 | Anti-HIV Agents (therapeutic use) |
| 294 | Cross-Sectional Studies |
| 285 | Child |
| 271 | Health Knowledge, Attitudes, Practice |
| 270 | HIV Infections (transmission) |
| 263 | Surveys and Questionnaires |
| 232 | HIV Infections (complications) |
| 217 | Pregnancy |
| 203 | HIV Infections (diagnosis) |
| 203 | CD4 Lymphocyte Count |
| 169 | HIV Infections (virology) |
| 163 | Africa South of the Sahara (epidemiology) |
| 160 | Aged |
| 158 | Infant |
| 146 | Child, Preschool |
| 142 | Anti-Retroviral Agents (therapeutic use) |
| 141 | Qualitative Research |
| 134 | HIV Infections (immunology) |
| 133 | Sexual Behavior |
| 130 | Risk-Taking |
| 130 | Africa South of the Sahara |
| 129 | Viral Load |
| 127 | Acquired Immunodeficiency Syndrome (epidemiology) |
| 125 | Interviews as Topic |
| 124 | Developing Countries |
| 119 | Social Support |
| 118 | Treatment Outcome |
| 116 | Rural Population |
| 115 | Antiretroviral Therapy, Highly Active |
| 114 | HIV Infections (mortality) |
| 113 | Sexual Partners |
| 113 | Infectious Disease Transmission, Vertical (prevention & control) |
| 113 | Cohort Studies |
| 111 | Social Stigma |
| 107 | Incidence |
| 104 | Sex Factors |
| 103 | Prospective Studies |
| 96 | Health Services Accessibility |
| 96 | Age Factors |
| 95 | Retrospective Studies |
| 95 | Infant, Newborn |
| 89 | HIV Infections (therapy) |
| 89 | HIV Infections (economics) |
| 86 | HIV-1 |
| 84 | Acquired Immunodeficiency Syndrome (prevention & control) |
| 83 | Focus Groups |
| 83 | Condoms (utilization) |
| 80 | Logistic Models |
| 78 | Zambia |
| 78 | Anti-HIV Agents (administration & dosage) |
| 77 | AIDS-Related Opportunistic Infections (epidemiology) |
| 72 | HIV Infections (ethnology) |
| 70 | Counseling |
| 70 | Acquired Immunodeficiency Syndrome (psychology) |
| 68 | Time Factors |
| 67 | Tuberculosis (epidemiology) |
| 67 | Sexual Behavior (psychology) |
| 67 | Health Surveys |
| 66 | HIV-1 (genetics) |
| 65 | Acquired Immunodeficiency Syndrome (drug therapy) |
| 63 | Zambia (epidemiology) |
| 62 | Urban Population |
| 60 | Poverty |
| 59 | Sexual Behavior (statistics & numerical data) |
| 59 | Patient Acceptance of Health Care (statistics & numerical data) |
| 59 | Follow-Up Studies |
| 58 | HIV-1 (immunology) |
| 57 | Family Characteristics |
| 56 | HIV Infections |
| 56 | Africa |
| 55 | Program Evaluation |
| 55 | Patient Acceptance of Health Care |
| 55 | Medication Adherence |
| 55 | Educational Status |
| 54 | HIV-1 (isolation & purification) |
| 53 | Health Policy |
| 53 | HIV-1 (drug effects) |
| 52 | AIDS-Related Opportunistic Infections (drug therapy) |
| 51 | Antiretroviral Therapy, Highly Active (methods) |
| 50 | Prejudice |
| 50 | Patient Acceptance of Health Care (psychology) |
| 50 | Global Health |
| 50 | Acquired Immunodeficiency Syndrome |
| 49 | Uganda (epidemiology) |
| 48 | Stereotyping |
| 47 | Medication Adherence (statistics & numerical data) |
| 46 | Multivariate Analysis |
| 45 | Longitudinal Studies |
| 45 | HIV Seropositivity (epidemiology) |
| 45 | Caregivers (psychology) |
| 45 | Attitude to Health |
| 44 | Tuberculosis (drug therapy) |
| 44 | Culture |
| 43 | Medication Adherence (psychology) |
| 43 | Interpersonal Relations |
| 43 | Demography |
| 43 | Aged, 80 and over |
| 41 | Sexual Partners (psychology) |
| 41 | Population Surveillance |
| 41 | Acquired Immunodeficiency Syndrome (transmission) |
| 40 | Risk Assessment |
| 40 | HIV |
| 40 | Antitubercular Agents (therapeutic use) |
| 40 | Anti-HIV Agents (adverse effects) |
| 40 | Adaptation, Psychological |
| 40 | Acquired Immunodeficiency Syndrome (economics) |
| 39 | Age Distribution |
| 39 | Acquired Immunodeficiency Syndrome (complications) |
| 38 | Pregnancy Complications, Infectious (drug therapy) |
| 38 | HIV Seropositivity (psychology) |
| 38 | Disease Progression |
| 37 | Ghana |
| 37 | Genotype |
| 36 | Uganda |
| 36 | Rural Population (statistics & numerical data) |
| 36 | Pilot Projects |
| 36 | Motivation |
| 36 | HIV Infections (blood) |
| 36 | Case-Control Studies |
| 36 | Acquired Immunodeficiency Syndrome (mortality) |
| 35 | Sex Distribution |
| 35 | AIDS Serodiagnosis |
| 34 | Truth Disclosure |
| 34 | Residence Characteristics |
| 34 | Randomized Controlled Trials as Topic |
| 34 | Quality of Life |
| 34 | Health Services Needs and Demand |
| 34 | Disease Outbreaks |
| 34 | AIDS-Related Opportunistic Infections (diagnosis) |
| 33 | Pregnancy Complications, Infectious (epidemiology) |
| 33 | Communication |
| 33 | Animals |
| 32 | Social Class |
| 32 | Regression Analysis |
| 32 | Pregnancy Complications, Infectious (prevention & control) |
| 32 | Politics |
| 32 | International Cooperation |
| 32 | Health Status |
| 32 | HIV Infections (pathology) |
| 31 | Virus Diseases |
| 31 | Kenya |
| 31 | Disease |
| 31 | Comorbidity |
| 30 | Risk Reduction Behavior |
| 30 | Patient Compliance |
| 30 | Odds Ratio |
| 30 | Drug Therapy, Combination |
| 29 | Zimbabwe (epidemiology) |
| 29 | Social Environment |
| 29 | Models, Theoretical |
| 29 | Mass Screening |
| 29 | Kenya (epidemiology) |
| 29 | Health Education |
| 29 | HIV Seropositivity (drug therapy) |
| 29 | Economics |
| 29 | African Continental Ancestry Group |
| 28 | Tanzania (epidemiology) |
| 27 | Tuberculosis (complications) |
| 27 | Cost-Benefit Analysis |
| 27 | Attitude of Health Personnel |
| 27 | Africa (epidemiology) |
| 26 | Survival Analysis |
| 26 | Sexually Transmitted Diseases (prevention & control) |
| 26 | Malawi |
| 26 | Ghana (epidemiology) |
| 26 | Drug Resistance, Viral |
| 26 | AIDS-Related Opportunistic Infections (microbiology) |
| 26 | AIDS-Related Opportunistic Infections (immunology) |
| 25 | Sexually Transmitted Diseases (epidemiology) |
| 25 | Perception |
| 25 | Homosexuality, Male |
| 25 | Anti-HIV Agents (economics) |
| 25 | AIDS-Related Opportunistic Infections (mortality) |
| 24 | Vulnerable Populations |
| 24 | Unsafe Sex (statistics & numerical data) |
| 24 | Mass Screening (methods) |
| 24 | Alcohol Drinking (epidemiology) |
| 24 | Acquired Immunodeficiency Syndrome (ethnology) |
| 23 | Phylogeny |
| 23 | Mothers (psychology) |
| 23 | Health Services Accessibility (statistics & numerical data) |
| 23 | Health Behavior |
| 23 | HIV-1 (classification) |
| 23 | Cultural Characteristics |
| 22 | World Health Organization |
| 22 | Reproducibility of Results |
| 22 | HIV Infections (physiopathology) |
| 22 | Epidemiologic Methods |
| 22 | Drug Administration Schedule |
| 22 | Decision Making |
| 22 | AIDS-Related Opportunistic Infections (prevention & control) |
| 21 | Zimbabwe |
| 21 | Women's Health |
| 21 | Tanzania |
| 21 | Poverty (statistics & numerical data) |
| 21 | Nigeria (epidemiology) |
| 21 | Mothers |
| 21 | Infectious Disease Transmission, Vertical |
| 21 | Health Promotion |
| 21 | HIV Infections (genetics) |
| 21 | Feasibility Studies |
| 21 | Cost of Illness |
| 21 | Condoms |
| 21 | Acquired Immunodeficiency Syndrome (therapy) |
| 21 | AIDS Vaccines (immunology) |
| 20 | Tuberculosis, Pulmonary (epidemiology) |
| 20 | Tuberculosis (prevention & control) |
| 20 | Tuberculosis (immunology) |
| 20 | Sexual Behavior (ethnology) |
| 20 | Quality of Life (psychology) |
| 20 | Pregnancy Complications, Infectious (diagnosis) |
| 20 | Population |
| 20 | Nigeria |
| 20 | Malawi (epidemiology) |
| 20 | HIV Seropositivity (diagnosis) |
| 20 | Family |
| 20 | Counseling (utilization) |
| 20 | Antiretroviral Therapy, Highly Active (adverse effects) |
| 20 | Adolescent Behavior |
| 20 | AIDS-Related Opportunistic Infections (complications) |
| 19 | Severity of Illness Index |
| 19 | Sensitivity and Specificity |
| 19 | Senegal |
| 19 | Population Dynamics |
| 19 | Patient Compliance (statistics & numerical data) |
| 19 | Nevirapine (therapeutic use) |
| 19 | HIV-1 (physiology) |
| 19 | HIV Seropositivity |
| 19 | Cluster Analysis |
| 19 | Child, Orphaned (statistics & numerical data) |
| 19 | Cause of Death |
| 19 | Anti-Retroviral Agents (administration & dosage) |
| 19 | Acquired Immunodeficiency Syndrome (immunology) |
| 18 | Unsafe Sex (psychology) |
| 18 | United States |
| 18 | Tuberculosis, Pulmonary (drug therapy) |
| 18 | Tuberculosis (diagnosis) |
| 18 | Treatment Failure |
| 18 | Tenofovir |
| 18 | Sequence Analysis, DNA |
| 18 | RNA, Viral (blood) |
| 18 | Proportional Hazards Models |
| 18 | Health Status Disparities |
| 18 | Health Services Research |
| 18 | Health Promotion (methods) |
| 18 | Health Education (methods) |
| 18 | Health Care Surveys |
| 18 | HIV Seroprevalence |
| 18 | Delivery of Health Care |
| 18 | Coinfection |
| 18 | Child, Orphaned |
| 18 | Ambulatory Care Facilities |
| 18 | Africa South of the Sahara (ethnology) |
| 18 | Adenine (analogs & derivatives) |
| 17 | Urban Population (statistics & numerical data) |
| 17 | Self Report |
| 17 | Research Design |
| 17 | Primary Health Care |
| 17 | Patient Education as Topic |
| 17 | Molecular Sequence Data |
| 17 | Home Care Services |
| 17 | History, 20th Century |
| 17 | Delivery of Health Care (economics) |
| 17 | Breast Feeding |
| 17 | Anti-HIV Agents (pharmacology) |
| 17 | AIDS Serodiagnosis (utilization) |
| 16 | Tuberculosis (mortality) |
| 16 | Stress, Psychological (psychology) |
| 16 | Self Efficacy |
| 16 | Self Disclosure |
| 16 | Schools |
| 16 | Safe Sex |
| 16 | Rural Health |
| 16 | Risk |
| 16 | Research |
| 16 | Prognosis |
| 16 | Pregnancy Complications, Infectious (virology) |
| 16 | Pregnancy Complications, Infectious (psychology) |
| 16 | Practice Guidelines as Topic |
| 16 | Health Services Accessibility (economics) |
| 16 | HIV-1 (pathogenicity) |
| 16 | HIV Infections (nursing) |
| 16 | Genetic Variation |
| 16 | Epidemics |
| 16 | Disclosure |
| 16 | Data Collection |
| 16 | Counseling (methods) |
| 16 | Clinical Trials as Topic |
| 16 | CD4-Positive T-Lymphocytes (immunology) |
| 16 | Body Mass Index |
| 15 | Viral Load (drug effects) |
| 15 | Mycobacterium tuberculosis (isolation & purification) |
| 15 | Mutation |
| 15 | Homosexuality, Male (psychology) |
| 15 | Developing Countries (statistics & numerical data) |
| 15 | Community Health Services |
| 15 | Antitubercular Agents (adverse effects) |
| 15 | Algorithms |
| 15 | Africa, Southern |
| 14 | United States (epidemiology) |
| 14 | Tuberculosis, Pulmonary (diagnosis) |
| 14 | South Africa (ethnology) |
| 14 | Sex Work |
| 14 | Seroepidemiologic Studies |
| 14 | Psychiatric Status Rating Scales |
| 14 | Professional-Patient Relations |
| 14 | Prenatal Care |
| 14 | Power (Psychology) |
| 14 | Peer Group |
| 14 | Marital Status |
| 14 | Kaplan-Meier Estimate |
| 14 | Health Personnel (psychology) |
| 14 | HIV Seronegativity |
| 14 | Evaluation Studies as Topic |
| 14 | Enzyme-Linked Immunosorbent Assay |
| 14 | Discrimination (Psychology) |
| 14 | Delivery of Health Care (organization & administration) |
| 14 | Cross-Cultural Comparison |
| 14 | Coinfection (epidemiology) |
| 14 | Africa, Eastern |
| 14 | Administration, Intravaginal |
| 13 | gag Gene Products, Human Immunodeficiency Virus (genetics) |
| 13 | Unsafe Sex |
| 13 | United Nations |
| 13 | Tuberculosis, Pulmonary (complications) |
| 13 | Transients and Migrants |
| 13 | Substance-Related Disorders (epidemiology) |
| 13 | Sputum (microbiology) |
| 13 | Senegal (epidemiology) |
| 13 | Sampling Studies |
| 13 | Religion |
| 13 | Policy Making |
| 13 | Needs Assessment |
| 13 | Mass Screening (utilization) |
| 13 | Marriage |
| 13 | Lost to Follow-Up |
| 13 | Infectious Disease Transmission, Vertical (statistics & numerical data) |
| 13 | Ethiopia |
| 13 | Depression (psychology) |
| 13 | Depression (epidemiology) |
| 13 | Condoms (statistics & numerical data) |
| 13 | Community Health Services (organization & administration) |
| 13 | Attitude to Health (ethnology) |
| 13 | Acquired Immunodeficiency Syndrome (diagnosis) |
| 13 | AIDS-Related Opportunistic Infections (pathology) |
| 13 | AIDS Vaccines (administration & dosage) |
| 13 | AIDS Serodiagnosis (methods) |
| 12 | Social Perception |
| 12 | RNA, Viral (genetics) |
| 12 | Program Development |
| 12 | Patient Compliance (psychology) |
| 12 | Neoplasms (epidemiology) |
| 12 | Mental Health |
| 12 | Medicine, African Traditional |
| 12 | Isoniazid (therapeutic use) |
| 12 | Intention |
| 12 | Income |
| 12 | History, 21st Century |
| 12 | Health Personnel |
| 12 | HIV Seropositivity (immunology) |
| 12 | HIV Infections (etiology) |
| 12 | HIV (isolation & purification) |
| 12 | Education |
| 12 | Communicable Disease Control (organization & administration) |
| 12 | Circumcision, Male |
| 12 | Circumcision, Male (statistics & numerical data) |
| 12 | Benzoxazines (therapeutic use) |
| 12 | African Continental Ancestry Group (statistics & numerical data) |
| 12 | Acquired Immunodeficiency Syndrome (history) |
| 12 | AIDS Serodiagnosis (statistics & numerical data) |
| 11 | Uterine Cervical Neoplasms (epidemiology) |
| 11 | Students (psychology) |
| 11 | Sex Education |
| 11 | Reverse Transcriptase Inhibitors (therapeutic use) |
| 11 | Public Health |
| 11 | Pregnant Women (psychology) |
| 11 | Pre-Exposure Prophylaxis |
| 11 | Poverty Areas |
| 11 | Poverty (psychology) |
| 11 | Population Surveillance (methods) |
| 11 | Population Characteristics |
| 11 | Morbidity |
| 11 | Mental Disorders (epidemiology) |
| 11 | Homosexuality, Male (statistics & numerical data) |
| 11 | Heterosexuality |
| 11 | Health Services Accessibility (standards) |
| 11 | Health Care Costs |
| 11 | HIV Seropositivity (complications) |
| 11 | Gender Identity |
| 11 | Forecasting |
| 11 | Food Supply |
| 11 | Family Health |
| 11 | Early Diagnosis |
| 11 | Confidence Intervals |
| 11 | Child, Orphaned (psychology) |
| 11 | Caregivers |
| 11 | Caregivers (statistics & numerical data) |
| 11 | CD8-Positive T-Lymphocytes (immunology) |
| 11 | Botswana (epidemiology) |
| 11 | Behavior |
| 11 | Anti-Infective Agents (therapeutic use) |
| 11 | Africa, Southern (epidemiology) |
| 10 | gag Gene Products, Human Immunodeficiency Virus (immunology) |
| 10 | Universities |
| 10 | Tuberculosis (microbiology) |
| 10 | Trimethoprim, Sulfamethoxazole Drug Combination (therapeutic use) |
| 10 | Swaziland (epidemiology) |
| 10 | Social Behavior |
| 10 | Sexually Transmitted Diseases (transmission) |
| 10 | Self Concept |
| 10 | Referral and Consultation |
| 10 | Prenatal Care (methods) |
| 10 | Pregnancy Complications, Infectious |
| 10 | Polymorphism, Single Nucleotide |
| 10 | Parents (psychology) |
| 10 | Organophosphonates (therapeutic use) |
| 10 | Organophosphonates (administration & dosage) |
| 10 | Organization and Administration |
| 10 | National Health Programs |
| 10 | Mothers (statistics & numerical data) |
| 10 | Mortality |
| 10 | Models, Statistical |
| 10 | Mental Disorders (psychology) |
| 10 | Leadership |
| 10 | Human Rights |
| 10 | HIV Seropositivity (transmission) |
| 10 | HIV Infections (metabolism) |
| 10 | Fertility |
| 10 | Drug Resistance, Viral (genetics) |
| 10 | Cooperative Behavior |
| 10 | Confidentiality |
| 10 | Biomarkers (blood) |
| 10 | Antitubercular Agents (administration & dosage) |
| 10 | Antiretroviral Therapy, Highly Active (economics) |
| 10 | Antifungal Agents (therapeutic use) |
| 10 | Adolescent Behavior (psychology) |
| 10 | Adenine (therapeutic use) |
| 10 | Adenine (administration & dosage) |
| 10 | Acquired Immunodeficiency Syndrome (virology) |
| 10 | AIDS-Related Opportunistic Infections (virology) |
| 10 | AIDS Vaccines (therapeutic use) |
| 9 | Zidovudine (therapeutic use) |
| 9 | Women (psychology) |
| 9 | Vulnerable Populations (statistics & numerical data) |
| 9 | Voluntary Programs (utilization) |
| 9 | Tuberculosis, Multidrug-Resistant (drug therapy) |
| 9 | Survival Rate |
| 9 | Substance-Related Disorders (complications) |
| 9 | Spouse Abuse (psychology) |
| 9 | Sex Workers |
| 9 | Sentinel Surveillance |
| 9 | Sarcoma, Kaposi (epidemiology) |
| 9 | Reverse Transcriptase Inhibitors (adverse effects) |
| 9 | Public Policy |
| 9 | Polymorphism, Genetic |
| 9 | Patient Acceptance of Health Care (ethnology) |
| 9 | Parent-Child Relations |
| 9 | Outcome Assessment (Health Care) |
| 9 | Nutritional Status |
| 9 | Neuropsychological Tests |
| 9 | Mortality (trends) |
| 9 | Models, Organizational |
| 9 | Models, Biological |
| 9 | Microbial Sensitivity Tests |
| 9 | Medication Adherence (ethnology) |
| 9 | Malnutrition (complications) |
| 9 | Lamivudine (therapeutic use) |
| 9 | Hospitals, Teaching |
| 9 | Healthcare Disparities |
| 9 | Health Services (utilization) |
| 9 | HIV Infections (microbiology) |
| 9 | HIV Antibodies (immunology) |
| 9 | HIV (genetics) |
| 9 | Geography |
| 9 | Flow Cytometry |
| 9 | Ethiopia (epidemiology) |
| 9 | Emigration and Immigration |
| 9 | Emigrants and Immigrants (statistics & numerical data) |
| 9 | Drug Interactions |
| 9 | Double-Blind Method |
| 9 | Diabetes Mellitus (epidemiology) |
| 9 | Depressive Disorder (epidemiology) |
| 9 | Depression (etiology) |
| 9 | Depression (diagnosis) |
